Fecal Microbiota Transplantation for Irritable Bowel Syndrome
Condition(s) studied
Investigational drug(s) / intervention(s)
fecal microbiota transplantation: 200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
Infusion of sham: Infusion of sham
probiotics, antibiotics or antidepressants: Drugs such as probiotics, antibiotics, antidepressants
Study summary
Fecal microbiota transplantation (FMT) is a strategy that infuses a fecal suspension containing a healthy donor's microbiota into a patient's gut to restore his/her intestinal microbiome. FMT has a higher cure rate than standard antibiotic treatment for recurrent Clostridium difficile infections,and shows promising results in Inflammatory bowel disease(IBD).However, few studies have evaluated whether FMT is effective to treat Irritable bowel syndrome(IBS).The investigators propose to determine the efficiency and safety of FMT in patients with Irritable bowel syndrome.
Eligibility
Primary outcome measure(s)
- Change in Irritable Bowel Syndrome assessed by Symptom Severity Score (IBS-SSS) — baseline; one month;three months;six months
This questionnaire was used for assessing IBS severity. Scores of five questions were calculated with the Visual Analogue Scale (VAS) scale: the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distention, dissatisfaction with bowel habits and interference with quality of life. The scores ranged from 0 to 500, a higher score indicating worse condition :\<75 indicated remission; 75-175 indicated mild IBS;176-300 indicated moderate IBS; and \> 300 indicated severe IBS .
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Guangzhou First People's Hospital | Guangzhou | Guangdong | Recruiting |
More Guangzhou First People's Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03613545 on ClinicalTrials.gov ↗ ← All trials in China